UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

European journal of pharmacology, 2013-09, Vol.715 (1-3), p.246-255

2013

Volltextzugriff (PDF)

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

European journal of pharmacology, 2014-03, Vol.727, p.66-74

2014

Volltextzugriff (PDF)

Ipragliflozin: First Global Approval

Drugs (New York, N.Y.), 2014-04, Vol.74 (5), p.611-617

2014

Volltextzugriff (PDF)

The antidiabetic drug ipragliflozin induces vasorelaxation of rabbit femoral artery by activating a Kv channel, the SERCA pump, and the PKA signaling pathway

European journal of pharmacology, 2024-06, Vol.972, p.176589-176589, Article 176589

2024

Volltextzugriff (PDF)

iPreny-PseAAC: Identify C-terminal Cysteine Prenylation Sites in Proteins by Incorporating Two Tiers of Sequence Couplings into PseAAC

Medicinal chemistry (Shp-sariqah, United Arab Emirates), 2017-09, Vol.13 (6), p.544

2017

Volltextzugriff (PDF)

Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats

Psychopharmacology, 2017-10, Vol.234 (20), p.3037-3053

2017

Volltextzugriff (PDF)

A molecularly imprinted polymer-based detection platform confirmed through molecular modeling for the highly sensitive and selective analysis of ipratropium bromide

Journal of pharmaceutical and biomedical analysis, 2024-09, Vol.248, p.116283, Article 116283

2024

Volltextzugriff (PDF)

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

European journal of pharmacology, 2015-05, Vol.754, p.19-24

2015

Volltextzugriff (PDF)

Ipragliflozin and other sodium―glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

Pharmacology & therapeutics (Oxford), 2013-07, Vol.139 (1), p.51-59

2013

Volltextzugriff (PDF)

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Journal of pharmacy and pharmacology, 2014-07, Vol.66 (7), p.975-987

2014

Volltextzugriff (PDF)

The forgotten material: Highly dispersible and swellable gelatin-based microspheres for pulmonary drug delivery of cromolyn sodium and ipratropium bromide

International journal of pharmaceutics, 2023-09, Vol.644, p.123331-123331, Article 123331

2023

Volltextzugriff (PDF)

Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction

Pharmacotherapy, 2023-12, Vol.43 (12), p.1317-1326

2023

Volltextzugriff (PDF)

Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial

Journal of clinical psychopharmacology, 2024-01, Vol.44 (1), p.9-15

2024

Volltextzugriff (PDF)

Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy

Life sciences (1973), 2019-08, Vol.230, p.19-27

2019

Volltextzugriff (PDF)

Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice

European journal of pharmacology, 2018-07, Vol.830, p.68-75

2018

Volltextzugriff (PDF)

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Bioorganic & medicinal chemistry, 2012-05, Vol.20 (10), p.3263-3279

2012

Volltextzugriff (PDF)

The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy

Biological and Pharmaceutical Bulletin, 2022/09/01, Vol.45(9), pp.1321-1331

Takasu, Toshiyuki

2022

Volltextzugriff (PDF)

Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes

Expert opinion on pharmacotherapy, 2017-09, Vol.18 (14), p.1433-1438

2017

Volltextzugriff (PDF)

Incorporation and effects of mesoporous SiO2-CaO nanospheres loaded with ipriflavone on osteoblast/osteoclast cocultures

European journal of pharmaceutics and biopharmaceutics, 2018-12, Vol.133, p.258-268

2018

Volltextzugriff (PDF)

Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH

European journal of pharmacology, 2021-06, Vol.901, p.174076-174076, Article 174076

Tahara, Atsuo

2021

Volltextzugriff (PDF)

Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats

Life sciences (1973), 2016-02, Vol.147, p.125-131

2016

Volltextzugriff (PDF)

Treprostinil Supplementation Ameliorates Hepatic Ischemia Reperfusion Injury and Regulates Expression of Hepatic Drug Transporters: An Isolated Perfused Rat Liver (IPRL) Study

Pharmaceutical research, 2022-11, Vol.39 (11), p.2979-2990

2022

Volltextzugriff (PDF)

The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis

Pharmacological research, 2020-09, Vol.159, p.104860-104860, Article 104860

2020

Volltextzugriff (PDF)

Interactions of casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4 enzymes

Biomedicine & pharmacotherapy, 2018-11, Vol.107, p.777-784

2018

Volltextzugriff (PDF)

SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice

European journal of pharmacology, 2021-11, Vol.910, p.174486-174486, Article 174486

Tahara, Atsuo

2021

Volltextzugriff (PDF)

1 – 25 von 7.189

Suche als RSS-Feed

Aktive Filter

PublikationsformBuchkapitel

ThemaPharmacology & Pharmacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.781)
Mit Volltextzugriff
(5.704)

Publikationsform

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(5.046)
Journals@Ovid Complete
(3.128)
Ingenta
(3.062)
EZB Free E-Journals
(2.557)
Wiley Online Library
(1.818)
IngentaConnect Journals
(1.761)
Springer Journals
(1.554)
Wiley Online Library
(1.229)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(924)
Taylor & Francis Journals Auto-Holdings Collection
(829)
Elsevier ScienceDirect Journals Complete
(800)
Publisher website
(723)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(712)
Taylor & Francis Current Content Access
(623)
Nexis Uni
(603)
Taylor & Francis Online
(521)
SAGE Journals Online
(230)
Oxford University Press Journals Current
(151)
Nature Journals
(139)
Oxford Journals 2020 Medicine
(78)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(32)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Ipragliflozin: First Global Approval

The antidiabetic drug ipragliflozin induces vasorelaxation of rabbit femoral artery by activating a Kv channel, the SERCA pump, and the PKA signaling pathway

iPreny-PseAAC: Identify C-terminal Cysteine Prenylation Sites in Proteins by Incorporating Two Tiers of Sequence Couplings into PseAAC

Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats

A molecularly imprinted polymer-based detection platform confirmed through molecular modeling for the highly sensitive and selective analysis of ipratropium bromide

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

Ipragliflozin and other sodium―glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

The forgotten material: Highly dispersible and swellable gelatin-based microspheres for pulmonary drug delivery of cromolyn sodium and ipratropium bromide

Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction

Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial

Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy

Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy

Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes

Incorporation and effects of mesoporous SiO2-CaO nanospheres loaded with ipriflavone on osteoblast/osteoclast cocultures

Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH

Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats

Treprostinil Supplementation Ameliorates Hepatic Ischemia Reperfusion Injury and Regulates Expression of Hepatic Drug Transporters: An Isolated Perfused Rat Liver (IPRL) Study

The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis

Interactions of casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4 enzymes

SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice

Aktive Filter

Suchergebnisse filtern